Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CATCO-NOS: Monoclonal Antibodies for Nosocomial COVID-19
NCT04748588Phase 4Terminated
- Sponsor
- University of Calgary
- Start
- Feb 2021
- Primary completion
- Jan 2022
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by University of Calgary. Primary endpoint: Proportion of participants requiring mechanical ventilation or not surviving to hospital discharge at 60 days. Started Feb 2021; status: terminated.
02
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04748588.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04748588.